Product Images Cisatracurium Besylate

This is a description of Cisatracurium Besylate injection, a medication used as a paralyzing agent for intravenous injection. It comes in a 10 mg/5 mL single-dose vial and should be discarded if any portion is unused. This solution should only be administered by healthcare professionals in facilities equipped for artificial respiration as it may cause respiratory arrest. The medication contains benzenesulfonic acid to adjust the pH. It is recommended to store the medication between 36°F to 46°F and use it within 21 days after removal from refrigeration, even if kept refrigerated. The injection is manufactured by Grand Pharma Limited in Hyderabad, India.*

This text is a warning for Cisatracurium Besylate Injection, a paralyzing agent that may lead to respiratory arrest. The concentration of the injection is given in mg/mL.*

This is a warning message about Cisatracurium Besylate Injection, USP, which contains a paralyzing agent that can lead to respiratory arrest. The product appears to have a concentration of mg per mL. It is essential to handle this medication with caution due to its potential serious effects.*

This is a warning text for a paralyzing agent called Cisatracurium Besylate Injection, USP, which can cause respiratory arrest. The concentration of the injection is listed as mg/mL.*

This text provides information about a pharmaceutical product containing cisatracurium as an active ingredient, labeled as a paralyzing agent used for intravenous injection. The formulation includes cisatracurium besylate, benzy! alcohol, and instructions for storage at a specific temperature range. The warnings highlight the risk of respiratory arrest and the necessity of facilities for artificial respiration. Additionally, there are guidelines for usage and disposal. The product is a 10 mL multiple-dose vial manufactured in Hyderabad, India.*

This is a description of a pharmaceutical product labeled with the NDC number 68083-487-01. The product is a paralyzing agent for intravenous injection containing cisatracurium. It is warned that the substance causes respiratory arrest and that facilities for artificial respiration must be immediately available. The product comes in a 20 mL single-dose vial with a concentration of 10 mg/mL, to be stored between 2° to 8°C (36° to 46°F) and protected from light. Once removed from refrigeration, it should be used within 3 weeks, even if refrigerated again. The manufacturer is Gland Pharma Limited, located in Hyderabad, India.*

This is a drug with NDC 68083-486-01, which is a paralyzing agent (Cisatracurium Besylate Injection, USP) used for intravenous injection. It is essential to have facilities for artificial respiration readily available as it can cause respiratory arrest. The medication should be stored between 2° to 8°C (36° to 46°F) and protected from light. Once removed from refrigeration, it must be used within 21 days, even if refrigerated again. The drug is manufactured by Gland Pharma in Hyderabad, India, and is available in a 5 mL single-dose vial.*